2027 Medicare Advantage and Part D Final Rule: What Agents Need to Know

CMS dropped the CY 2027 Medicare Advantage and Part D Final Rule on April 2, 2026, and it hits agents where it matters most: how you run events, how you handle SOAs, how you present disclaimers, and how you explain drug coverage. The rule takes effect June 1, 2026, covers plans starting January 1, 2027, and the marketing and communications provisions kick in October 1, 2026. 

This is not a paperwork update. It reshapes several parts of your sales workflow before AEP begins.

Here’s what you need to know.

What the Rule Actually Does

At a high level, the CY 2027 final rule does four things:

1. Simplifies the Star Ratings methodology
2. Locks in the Part D redesign changes from the Inflation Reduction Act
3. Loosens several outreach and appointment rules
4. Rolls back certain administrative requirements

It also confirms what did not make the cut, which matters just as much as what did. 

Star Ratings Got Leaner

CMS made two significant changes to Star Ratings.

First, it dropped the Excellent Health Outcomes for All reward (formerly the Health Equity Index reward) for the 2027 Star Ratings and returned to the historical reward factor. Second, it cut 11 measures from the rating set, all focused on administrative processes or areas where plan performance is so similar that beneficiaries cannot distinguish between them anyway.

One addition: a new Part C Depression Screening and Follow-Up measure, starting with the 2027 measurement year and landing in the 2029 Star Ratings.

What this means for you: Star Ratings drive quality bonus payments, rebates, and plan competitiveness. When CMS trims the measure set and focuses more on clinical outcomes and member experience, it raises the stakes for clean enrollments and strong plan fit. The agents who match clients to the right plan rather than just the right premium tend to win longer-term. 

Part D Is Now Codified

The IRA-driven Part D redesign has been operating through temporary program instruction authority. That authority expires, so CMS made it permanent for 2027 and beyond.

Key changes now codified:

• No more coverage gap phase

• Lower annual out-of-pocket threshold

•  No enrollee cost sharing in the catastrophic phase

• The Manufacturer Discount Program (which replaced the Coverage Gap Discount Program on January 1, 2025) is now in regulation

What this means for you: These are not new concepts, but they are now firmly embedded in the regulatory framework. Beneficiaries will ask how their drug costs work. If you cannot explain the redesigned Part D structure clearly, you are leaving trust on the table. For agencies, drug coverage education needs to be a core part of agent training, not an afterthought.  

The SOA and Event Rules You’ve Been Waiting On

This is the section that changes your day-to-day most. 

CMS finalized the removal of restrictions on the time and manner by which beneficiaries can have conversations with licensed agents and brokers. Specifically: 

• A marketing event can immediately follow an educational event at the same location, as long as beneficiaries are notified and given the opportunity to leave 
  
  
• The 48-hour waiting period between completing a Scope of Appointment and holding a personal marketing appointment is gone 
  
  
• SOA forms can now be made available and collected at educational events 

What this means for you: Less friction in your event workflow and appointment setting. Same-day follow-up is no longer a compliance problem. But the expectation for a non-pressured, transparent beneficiary experience does not change. These rules removed timing restrictions, not your responsibility to run clean business.

The TPMO Disclaimer Still Exists. The Timing Changed.

CMS modified, not eliminated, the TPMO disclaimer requirement.

The new rule: the disclaimer no longer needs to be delivered within the first minute of a call. It must be given before any plan benefits are discussed. CMS also removed SHIPs from the disclaimer language and kept the direction to Medicare.gov and 1-800-MEDICARE. 

The choice now sits with the consumer. This is actually good news in terms of reducing unexpected tax liabilities for clients, but it does mean more proactive communication is needed on your end. Do not assume your bronze plan clients are going to land in the right plan automatically during renewal season.

Supplemental Benefits: More Disclosure, Less Restriction Than Proposed

 CMS finalized transparency requirements around supplemental benefits, including:

• Plans must disclose all supplemental benefits, including conditions, limitations, and eligible OTC items

• Debit card administration requirements were tightened, including a reimbursement pathway when the card cannot be used and a real-time eligibility verification requirement at point of sale

• Plans must publicly post their plan-developed SSBCI eligibility criteria

What CMS did not finalize: The proposal to prohibit MA plans from marketing the dollar value of supplemental benefits or the delivery method (such as a debit card). That proposal was pulled.

What this means for you: Carriers still have room to lead with flex card and OTC messaging. But the disclosure requirements got stronger, not weaker. That means your explanations need to be accurate, not just attention-grabbing. 

One other update: Cannabis products illegal under state or federal law are not allowable as SSBCI. Certain hemp-seed-derived ingredients, such as hulled hemp seed, hemp seed protein powder, and hemp seed oil, may still qualify under FDA guidelines.

What Did Not Make the Final Rule

Two proposals that generated real industry discussion were not finalized:

1. Special enrollment period for provider terminations: CMS said it will continue to consider this in future rulemaking, but it is not in the final rule.

    

2. Prohibition on marketing supplemental benefit dollar values: As noted above, this did not survive the final rule.

Not every proposed change becomes regulation. Read the final rule, not just the proposed rule summaries. 

Other Deregulatory Changes Worth Knowing

CMS finalized several burden-reduction provisions:

• Account-based plans (HRAs, FSAs, HSAs) are exempt from creditable coverage disclosure requirements
  
  
• The mid-year notice about unused supplemental benefits is gone 
  
  
• The requirement for MA quality improvement programs to include health disparity reduction activities was removed 
  
  
• Health equity requirements for MA Utilization Management Committees, including mandatory health equity expert members and public posting of analyses, were eliminated 
  
  
• The LI NET toll-free call center hours requirement was waived